Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

DBV Technologies S.a. DBVT

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.6M
▲ 35.8% YoY
$-146.9M
$-121.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Our most advanced product candidate is Viaskin® Peanut Patch, which has been evaluated as a potential therapy for children with peanut allergy in twelve completed clinical trials, including five Phase 2 trials and five completed Phase 3 trials. The Company plans a BLA submission in the first half of 2026 for Viaskin Peanut Patch as a potential treatment for children four to seven years old. As of December 31, 2025, we had 125 full-time employees, including approximately 38 with M.D. or Ph.D. degrees, and one part-time employee.

Written from the business description in DBV Technologies S.A.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth

USD 5.6M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 5.6 · Net income -146.9
40M80M-100M-200M
201920222025
Compound annual growth
+5.2%
−13.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −13.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -2609.2% · Net ·
200%400%-1000%-2000%
201920222025
ROE
FY2025 · ROE -149.8%
20%40%60%-50%-100%
201920222025
Three returns, three denominators.

Each USD of equity lost 150 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -121.7
-100M-200M
201920222025

Total assetsUSD 233.7M
EquityUSD 168.8M
CashUSD 194.2M
Current ratio3.67×

Equity funds 72% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
DBVT, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.2−0.2
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.2◌
Income tax $B0.00.00.00.0−0.0−0.00.0
Net income $B−0.1−0.10.10.1−0.1−0.2−0.2
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.2−0.2
EPS, diluted $−1.05−1.17−0.76−1.24−1.78−2.95−4.65
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−149.8−136.043.565.6−64.2−80.0−103.6
Shares out B◌0.10◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures in 29 reconciliationsAUDITED

Reconciled in 5 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code I0
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image